Kevin Patterson, MD
Critical Care Medicine · Grand Rapids, MINPI 1457779274
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,515 of the $1,990 with a category attached, or 76.1%. Sanofi accounts for 79.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $1,667 and has fallen 84.2% since, to $263 in 2025.
Across 27 payments — averaging $73.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AstraZeneca$91
- GSK$88
- Verona Pharma, Inc.$53
- Regeneron Healthcare Solutions, Inc.$53
- Boehringer Ingelheim$33
- plus $91 from 4 others
Across 5 payments — averaging $29,714 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$149K
What the payments were for
- Consulting fees$1,51576%
- Food & beverage$47524%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 6 | $1,580 |
| AstraZeneca | 5 | $91 |
| GSK | 5 | $88 |
| Verona Pharma, Inc. | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 3 | $53 |
| Boehringer Ingelheim | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
| Viatris Specialty LLC | 1 | $18 |
| Mylan Specialty L.p. | 1 | $15 |
How this compares
$1,990 in reported general payments places this provider in the 80th percentile of 177 critical care medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 36 | $459,240 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 156 | $153,233 |
| Spiriva RespimatTiotropium Bromide | 167 | $137,707 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 88 | $45,526 |
| Breo ElliptaFluticasone/Vilanterol | 73 | $38,788 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 38 | $27,955 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 97 | $26,983 |
| DuleraMometasone/Formoterol | 62 | $26,162 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $25,889 |
| Qvar RedihalerBeclomethasone Dipropionate | 56 | $21,840 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $21,125 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $18,704 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 42 | $15,281 |
| Pulmicort FlexhalerBudesonide | 28 | $14,699 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $13,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $33 | $670,427329 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $88 | $237,439315 claims |
| AstraZenecaBreztri Aerosphere, Pulmicort Flexhaler, Symbicort | $91 | $53,95888 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 critical care medicine providers in Michigan.
Other critical care medicine in Grand Rapids
- Jeffery WiltGrand Rapids$10K
- Jason WellsGrand Rapids$8K
- Maximiliano Tamae KakazuGrand Rapids$7K
- Greg MarcoGrand Rapids$5K
- Joseph PitcherGrand Rapids$4K
- Noah JentzenGrand Rapids$2K
- Ruchira SenguptaGrand Rapids$2K
- Ghaleb KhirfanGrand Rapids$2K
- Malik KhanGrand Rapids$2K
- Kevin SwiatekGrand Rapids$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.